Scan to Download
One power score. Smarter investment decisions
Arrivent Biopharma Inc
AVBP18.580USD
+1.070+6.11%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
0.000USD0.000Pre-market 09/19, 09:30 (ET)
696.57MMarket Cap
LossP/E TTM
Arrivent Biopharma Inc
18.580
+1.070+6.11%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2022Q4
FY2022Q3
Operating cash flows (indirect method)
Cash flow from continuing operating activities
-36.87%-26.12M
-265.08%-68.01M
-8.31%-16.15M
-5.85%-16.34M
---19.09M
---18.63M
6.13%-14.91M
-55.57%-15.44M
---15.89M
---9.93M
Net income from continuing operations
-43.54%-31.40M
-269.68%-64.39M
2.64%-20.63M
-42.80%-20.56M
---21.87M
---17.42M
-102.96%-21.19M
-22.37%-14.40M
---10.44M
---11.77M
Other non-cash items
----
----
---192.47M
----
----
----
----
----
----
----
Change in working capital
-2.87%1.96M
-220.92%-5.89M
-40.80%3.53M
366.53%3.35M
--2.02M
---1.84M
207.25%5.96M
-172.76%-1.26M
---5.56M
--1.73M
-Change in prepaid expenses
-2032.93%-4.75M
-213.19%-1.59M
-64.66%1.43M
-86.35%298.00K
--246.00K
---508.00K
176.22%4.04M
167.29%2.18M
---5.30M
---3.24M
-Change in other current assets
----
100.00%0.00
97.14%-1.00K
-100.00%0.00
---18.00K
---1.00K
-3600.00%-35.00K
150.00%10.00K
--1.00K
--4.00K
Cash from non-recurring investing activities
Cash from operating activities
-36.87%-26.12M
-265.08%-68.01M
-8.31%-16.15M
-5.85%-16.34M
---19.09M
---18.63M
6.13%-14.91M
-55.57%-15.44M
---15.89M
---9.93M
Investing cash flow
Net cash flow from investment products
--13.91M
--36.82M
-869.86%-192.47M
----
----
----
--25.00M
--0.00
----
--0.00
Cash from non-current investing activities
Net cash flow from investing activities
--13.91M
--36.82M
-869.86%-192.47M
----
----
----
--25.00M
--0.00
--0.00
--0.00
Financing cash flow
Cash flow from continuous financing activities
20592.56%75.11M
-96.36%6.76M
105.20%55.00K
151.40%531.00K
--363.00K
--185.63M
-100.96%-1.06M
---1.03M
--109.72M
--0.00
Net cash flow from common stock issuance/repurchase
23517.87%75.34M
-96.49%6.52M
--0.00
--0.00
--319.00K
--185.63M
--0.00
--0.00
--0.00
--0.00
Net cash flow from preferred stock issuance/repurchase
----
----
----
----
----
--0.00
-100.00%0.00
--0.00
--109.71M
--0.00
Proceeds from stock option exercised by employees
72.73%76.00K
29200.00%293.00K
-80.70%55.00K
1261.54%531.00K
--44.00K
--1.00K
1800.00%285.00K
--39.00K
--15.00K
--0.00
Net cash flow from other financing activities
---303.00K
---50.00K
100.00%0.00
----
----
----
---1.34M
---1.07M
----
----
Net cash from non-recurrent financing activities
Net cash from financing activities
20592.56%75.11M
-96.36%6.76M
105.20%55.00K
151.40%531.00K
--363.00K
--185.63M
-100.96%-1.06M
---1.03M
--109.72M
--0.00
Net cash flow
Beginning cash balance
-84.29%49.87M
-50.60%74.29M
100.10%282.86M
89.23%298.67M
--317.39M
--150.39M
103.28%141.36M
98.62%157.83M
--69.54M
--79.46M
Current period cash flow changes
435.93%62.90M
-114.63%-24.43M
-2409.66%-208.56M
4.01%-15.81M
---18.72M
--167.00M
-90.38%9.03M
-65.98%-16.48M
--93.83M
---9.93M
Ending cash balance
-62.24%112.77M
-84.29%49.87M
-50.60%74.29M
100.10%282.86M
--298.67M
--317.39M
-7.95%150.39M
103.28%141.36M
--163.37M
--69.54M
Free cash flow
---26.12M
---68.01M
-8.31%-16.15M
----
----
----
---14.91M
-55.57%-15.44M
----
---9.93M
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
